Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA7 | P43166 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875526 | 0.87 | BID (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10174504 | 0.85 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16682991 | 0.84 | CA12 (0.74) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15129617 | 0.83 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26712747 | 0.82 | LMNA (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22745953 | 0.82 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30296784 | 0.82 | LMNA (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1519936 | 0.82 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11821465 | 0.81 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28104569 | 0.81 | CA12 (0.69) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7138543-B2 | Thiolalkyl benzoic acid derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20040198824-A1 | Thioalkyl benzoic acid derivatives | GUILFORD PHARMACEUTICALS INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1406867-A2 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | EISAI INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2002096866-A2 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198824-A1 | Thioalkyl benzoic acid derivatives | ALDH1A2, ALDH7A1, NAALAD2 | CA12 681/4885CA1 635/4885CA2 180/4885 |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | NAALAD2, DNPEP, ALDH7A1 | CA12 402/4885CA1 294/4885CA2 393/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | CA12 1088/4885CA1 1393/4885CA2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.